ARTICLE | Company News
Deerfield propels Civetta with $53M series A
How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class
December 5, 2019 1:20 AM UTC
Updated on Dec 7, 2019 at 1:18 AM UTC
Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome.
“There has been over time the emergence of data suggesting the propeller domain as a structure might be more amenable to drug discovery than people had previously thought,” said co-founder William Sellers. “There are close to 500 of these in the human genome, making it one of the most common structural domains.”...
BCIQ Company Profiles